Você procurou por: cytarabine (Inglês - Maltês)

cytarabine
cytarabine

cytarabine (n = 99 cycles)
cytarabine (n = 99 ċiklu)

the active substance is cytarabine.
is-sustanza attiva hi cytarabine.

cytarabine is an analogue of pyrimidine.
cytarabine huwa analogu għal pyrimidine.

each 5 ml vial contains 50 mg cytarabine
kull kunjett ta’ 5 ml fih 50 mg ta’ cytarabine.

4, 43) in the unencapsulated cytarabine arm.
4, 43) fil- parti ta ’ l- istudju b’ cytarabine li mhux f’ kapsuli.

depocyte 50 mg suspension for injection cytarabine
depocyte 50 mg suspensjoni għall-injezzjoni cytarabine

one ml of suspension contains 10 mg cytarabine.
millilitru wieħed ta’ suspensjoni fih 10 mg cytarabine.

each vial contains 50 mg cytarabine (10 mg/ml).
kull kunjett fih 50 mg ta’ cytarabine (10 mg/ml).

incorporation into dna and rna may also contribute to cytarabine cytotoxicity.
l- inkorporazzjoni f’dna u rna tista’ wkoll tikkontribwixxi għaċ-ċitotossiċità ta’ cytarabine.

each 5 ml vial contains 50 mg cytarabine (10 mg/ ml).
kull kunjett ta ’ 5 ml fih 50 mg ta ’ cytarabine (10 mg/ ml).

- the active substance is 50 mg cytarabine (10 mg/ ml)
- is- sustanza attiva hi 50 mg ta ’ cytarabine (10 mg/ ml)

anaphylactic reactions following intravenous administration of free cytarabine have been rarely reported.
reazzjonijiet anafilattiċi wara l-għoti minn ġol-vina ta’ cytarabine libera rarament kienu rrappurtati.

it is not known whether cytarabine is excreted in human milk following intrathecal administration.
mhuwiex magħruf jekk cytarabine joħroġhix imneħħija fil-ħalib tal-bniedem wara l-għoti ġot-teka.

depocyte is a suspension for injection that contains 50 mg of the active substance, cytarabine.
depocyte hija sospensjoni għall-injezzjoni li fiha 50 mg ta’ sustanza attiva cytarabine.

as a result, cytarabine slows down the growth of tumour cells and eventually kills them.
minħabba f’hekk, cytarabine jinibixxi ċ-ċelloli tat-tumur u eventwalment joqtolhom.

intrathecal co-administration of cytarabine with other cytotoxic agents may increase the risk of neurotoxicity.
l-għoti ġot-teka ta’ cytarabine flimkien ma’ mediċini ċitotossiċi oħrajn jista’ jżid ir-riskju ta’ newrotossiċità.

7 90% of cytarabine was excreted by day 4 and an additional 2.7% by 21 days.
iktar minn 90% ta ’ cytarabine tneħħa mil- ġisem sar- 4 jum u 2. 7% addizzjonali sal- 21 jum.

asparaginase may influence the efficacy of methotrexate or cytarabine (used to treat certain types of cancer):
asparaginase jista’ jinfluwenza l-effikaċja ta’ methotrexate jew cytarabine (jintużaw għall-kura ta’ ċerti tipi ta’ kanċer):

the proportion of patients alive at 12 months was 24% for depocyte versus 19% for unencapsulated cytarabine.
il-proporzjon ta’ pazjenti ħajjin wara 12-il xahar kien ta’ 24% għal depocyte kontra 19% għal cytarabine li mhux f’kapsuli.